Chemical Property of Mivacurium Chloride
Chemical Property:
- Appearance/Colour:Off-white solid
- PSA：144.90000
- LogP:2.95460
- Storage Temp.:Hygroscopic, -20°C Freezer, Under Inert Atmosphere
- Hydrogen Bond Donor Count:0
- Hydrogen Bond Acceptor Count:16
- Rotatable Bond Count:30
- Exact Mass:1098.4986606
- Heavy Atom Count:76
- Complexity:1550
- Purity/Quality:
-
99%, *data from raw suppliers
Mivacurium Chloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-]
- Isomeric SMILES:C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-]
- Recent ClinicalTrials:Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
- Recent EU Clinical Trials:MRI measurement of the effects of moderate versus deep neuromuscular blockade on the abdominal working space during laparoscopic surgery in a prospective cohort study.
-
Description
Mivacurium chloride,a mixture of three stereoisomers, is an intravenously
administered, short-acting skeletal muscle relaxant introduced as an adjunct to general
anesthesia. Structurally mivacurium chloride is closely related to doxacurium chloride
introduced in 1991 by Wellcome as a muscle relaxant. It is a nondepolarizing
neuromuscular blocking agent reportedly with a shorter duration of action and a more
rapid rate of spontaneous recovery than other nondepolarizing agents. In extensive
clinical trials mivacurium chloride was well tolerated with few side effects. Mivacurium is an antagonist of nicotinic acetylcholine receptors (nAChRs) and muscarinic M2 and M3 receptors (ED50s = 0.08, 0.3, and 0.1 mg/kg for ex vivo human skeletal muscle nAChRs, guinea pig cardiac M2 receptors, and guinea pig bronchial M3 receptors, respectively). It inhibits acetylcholine-induced activation of neuronal nAChRs (IC50s = 69.04, 3.71, 1.52, and 2.90 for human α3β2-, α3β4-, α4β2-, and α7-containing nAChRs expressed in Xenopus oocytes). Mivacurium also inhibits adult human muscular α1β1εδ-containing nAChRs (IC50 = 3.69 nM in Xenopus oocytes expressing the human recombinant receptor). In vivo, mivacurium inhibits bradycardia and bronchoconstriction induced by vagal stimulation or acetylcholine in guinea pigs. It also induces neuromuscular blockade (ED95 = 80 μg/kg) in sheep with a more rapid onset time than atracurium and vecuronium . Formulations containing mivacurium have been used for pediatric anesthesia.
-
Uses
Non-depolarizing neuromuscular blocking agent. Muscle relaxant (skeletal)
-
Therapeutic Function
Muscle relaxant
-
Biological Functions
Mivacurium chloride (Mivacron) is a newer agent
that is chemically related to atracurium. The primary
mechanism of inactivation is hydrolysis by plasma
cholinesterase. Although it is useful for patients with
renal or hepatic disease, some caution is warranted,
since these individuals may have reduced plasma
cholinesterase as a result of the disease.Mivacurium has
an onset of action (1.8 minutes) and duration of effect
(20 minutes) only twice that of succinylcholine, and in
this respect, it is the most similar to succinylcholine of
all of the nondepolarizing agents.
